Suppliers / Wuhan Biocause Pharmaceutical Development

Wuhan Biocause Pharmaceutical Development

China 3 employees Updated 9 July 2026

Wuhan Biocause Pharmaceutical Development is an API manufacturer based in China. Its GMP standing is certified by US FDA. Its most recent recorded inspection, by US FDA, closed on 14 March 2025 as VAI.

0
active US DMFs
0
valid CEPs
1
registered plants 1 with an FDA FEI number
0
filings across 0 regulators
These figures were checked against the regulators' own files on 25 July 2026
Plants
1 of 1 confirmed
Inspections
5 of 5 confirmed
Sources: FDA Establishment Registration, read 4 May 2026. FDA drug inspection classifications, read 4 May 2026.

Inspection history

  • 14 March 2025 VAI US FDA
  • 24 August 2018 VAI US FDA
  • 22 July 2016 VAI US FDA
  • 28 February 2014 VAI US FDA
  • 23 July 2010 VAI US FDA

NAI means no action indicated, VAI means voluntary action indicated, and OAI means official action indicated.

Registered plants

Site FDA FEI
China, China 3004202226

What they file, and where

Molecule Regulators Docs
Azacitidine SFDA (Saudi Arabia) 1
Flumazenil SFDA (Saudi Arabia) 1
Granisetron SFDA (Saudi Arabia) 1
Milrinone SFDA (Saudi Arabia) 1

Also appears on these molecule pages

Azacitidine API Flumazenil API Granisetron API Milrinone API

Filings and GMP by regulator

Regulator Filings GMP certificates
US FDA None 1

Questions about Wuhan Biocause Pharmaceutical Development

Is Wuhan Biocause Pharmaceutical Development FDA-registered?
One site operated by Wuhan Biocause Pharmaceutical Development carries an FDA establishment identifier (FEI), which means it is registered with the FDA as a drug establishment. Registration is not the same as approval or inspection clearance.
How did Wuhan Biocause Pharmaceutical Development's last inspection go?
The most recent inspection on record closed on 14 March 2025 as VAI (Voluntary Action Indicated: issues were found but did not warrant regulatory action). 5 inspections are on file.
Where does Wuhan Biocause Pharmaceutical Development manufacture?
1 registered site is on record, in China (China). Every site is listed on this page with the register it came from.
What does Wuhan Biocause Pharmaceutical Development make?
4 molecules are on record against Wuhan Biocause Pharmaceutical Development, including Azacitidine, Flumazenil, Granisetron and Milrinone. Each links through to that molecule's full manufacturer list.
Which regulators recognise Wuhan Biocause Pharmaceutical Development's GMP?
Current GMP certificates are on record from US FDA. GMP recognition covers the manufacturing site, separately from any filing on the substance itself.

Answered from this company's own record. Where a register holds nothing, the question is not asked rather than answered with a zero. How we count our figures.

Comparing suppliers?

Choose your molecules and target markets. Wuhan Biocause Pharmaceutical Development comes back tiered against every other supplier able to file there.

Start for free
No sales call.

Open risk flags

  • The most recent inspection outcome was VAI, on 14 March 2025.

Comparable suppliers

ScinoPharm Taiwan shares 3 molecules Hubei Biocause Heilen Pharmaceutical shares 3 molecules Dr Reddy's Laboratories shares 2 molecules Hikma shares 2 molecules Hubei Haosun Pharmaceutical shares 2 molecules

Ranked by shared active ingredients where we have them, otherwise by country and comparable credentials.

Sources on this page

FDA
Drug master files, establishment registration, inspection classifications
EDQM
Certificates of suitability
EudraGMDP and national regulators
GMP certificates